uniQure N.V. Faces Class Action Lawsuit Deadline

Berger Montague investigates potential securities fraud claims against the gene therapy company.

Apr. 6, 2026 at 6:30pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life image showing a single elegant glass vial filled with a glowing liquid, suspended against a clean white background, conceptually representing the complex and delicate nature of gene therapy research.A symbolic representation of the legal and scientific challenges facing pioneering gene therapy companies.Philadelphia Today

National plaintiffs' law firm Berger Montague has announced an upcoming deadline for a class action lawsuit against uniQure N.V., a gene therapy company based in Philadelphia. The lawsuit alleges potential securities fraud related to the company's business practices and disclosures.

Why it matters

As a leader in the gene therapy industry, any legal troubles for uniQure could have broader implications for public trust and investment in the field. The outcome of this lawsuit may set precedents around transparency and accountability for biotechnology firms.

The details

Berger Montague is investigating potential violations of federal securities laws by uniQure and certain of its officers. The lawsuit centers on allegations that the company made false and/or misleading statements and/or failed to disclose information pertinent to investors regarding its business, operations, and prospects.

  • The class action lawsuit deadline is approaching on April 18, 2026.

The players

uniQure N.V.

A gene therapy company based in Philadelphia that develops treatments for rare genetic diseases.

Berger Montague

A national plaintiffs' law firm that specializes in class action lawsuits and is investigating potential securities fraud claims against uniQure.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage investors who purchased uniQure securities to contact us to learn more about this investigation and their potential claims.”

— Sherrie R. Savett, Chair of the Securities Litigation Department at Berger Montague

What’s next

Investors have until April 18, 2026 to file a lead plaintiff motion in the class action lawsuit against uniQure.

The takeaway

This lawsuit highlights the importance of transparency and accountability for biotechnology firms as they develop potentially groundbreaking gene therapies. The outcome could impact public trust and investment in the industry.